14.05.2020 15:04:55

Press Release: Novartis data at ASCO and EHA -2-

Novartis is reimagining medicine to improve and extend people's lives.

As a leading global medicines company, we use innovative science and

digital technologies to create transformative treatments in areas of

great medical need. In our quest to find new medicines, we consistently

rank among the world's top companies investing in research and

development. Novartis products reach nearly 800 million people globally

and we are finding innovative ways to expand access to our latest

treatments. About 109,000 people of more than 145 nationalities work at

Novartis around the world. Find out more at https://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at


For Novartis multimedia content, please visit


For questions about the site or required registration, please contact


# # #

* Kisqali was developed by the Novartis Institutes for BioMedical

Research (NIBR) under a research collaboration with Astex


** Tabrecta is an oral and selective MET inhibitor licensed to Novartis

by Incyte Corporation in 2009. Under the Agreement, Incyte granted

Novartis worldwide exclusive development and commercialization rights to

capmatinib and certain back-up compounds in all indications.

*** Lutathera is a registered trademark of Advanced Accelerator

Applications, a Novartis company.

**** Jakavi is a registered trademark of Novartis AG in countries

outside the United States. Jakafi is a registered trademark of Incyte

Corporation. Novartis licensed ruxolitinib from Incyte Corporation for

development and commercialization outside the United States.

Novartis Media Relations

E-mail: media.relations@novartis.com

Anja von Treskow Julie Masow

Novartis External Communications Novartis Oncology Media Relations

+41 79 392 8697 (mobile) +1 862 778 7220 (direct)

anja.von_treskow@novartis.com +1 862 579 8456 (mobile)

Eric Althoff julie.masow@novartis.com

Novartis US External Communications

+1 646 438 4335


Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 862 778 3258

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

(END) Dow Jones Newswires

May 14, 2020 09:05 ET (13:05 GMT)

Analysen zu Novartis AGmehr Analysen

25.06.20 Novartis Neutral UBS AG
22.06.20 Novartis buy Oddo BHF
10.06.20 Novartis Conviction Buy List Goldman Sachs Group Inc.
03.06.20 Novartis Conviction Buy Goldman Sachs Group Inc.
21.05.20 Novartis Neutral UBS AG

Eintrag hinzufügen

Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!